Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

NCT01362400 is registered in ClinicalTrials.gov with Infinity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01362400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01362400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Lead sponsor
Infinity Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
April 30, 2014
Enrollment
226 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer